As an example of this paradoxical scenario, a 2 cm size tumour without nodal involvement can be treated, either with upfront surgery followed by mono-chemotherapy plus trastuzumab, or with neoadjuvant poly-chemotherapy plus dual HER2 blockade. Here, ERBB2 is linked to neoplasm.